| EW |
Report |
Total Revenue |
BEAT |
pred ~$1.75B vs. cons ~$1.72B |
MEDIUM |
| EW |
Report |
Adjusted EPS |
BEAT |
pred ~$0.78 vs. cons ~$0.745 |
MEDIUM |
| EW |
Report |
TAVR Segment Sales |
BEAT |
pred ~$1.25B vs. cons ~$1.22B |
MEDIUM |
| EW |
Guide |
FY2026 Total Revenue Guidance |
BETTER |
guide ~$6.75B vs. cons ~$6.72B (FY2026) |
MEDIUM |
| EW |
Guide |
FY2026 Adjusted EPS Guidance |
BETTER |
guide ~$3.02 vs. cons ~$3.00 (FY2026) |
MEDIUM |
| EW |
Guide |
FY2026 TAVR Constant-Currency Growth Guidance |
UNCHANGED |
guide ~8% vs. cons ~8% (FY2026, 7-9% range reaffirmed) |
LOW |
| EW |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
MEDIUM |
| EW |
Return |
5-day cumulative residual |
+5.5% (FOLLOW-THROUGH) |
Stock fell ~11% into the print on sector-wide TAVR sentiment (Medtronic commentary) and an unrelated FTC penalty headline, not company-specific fundamentals. A modest Q2 beat with reaffirmed/slightly raised FY26 guide (revenue, EPS) and continued TAVR/TMTT momentum should validate that the selloff was overdone, prompting sell-side price-target reiterations/upgrades (avg PT ~$97-98 vs ~$84 current) over the following days as analysts digest TMTT trajectory, CMS NCD commentary, and new CFO's tone, pulling the stock back toward pre-selloff highs. Risk to follow-through is the flagged tougher H2 comps capping the magnitude of upward estimate revisions. |
LOW |